<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>Results</title>
    <link rel="stylesheet" href="./lib/css/styles.css">
</head>
<body class="results">
<p><strong>Chronic&nbsp; liver&nbsp; disease.&nbsp; No&nbsp; prior&nbsp; diagnosis&nbsp; of&nbsp; hepatocellular&nbsp; carcinoma&nbsp; (HCC).&nbsp; Screening&nbsp; and surveillance for HCC.</strong></p>
<p><strong>Advice from : </strong><a href="https://acsearch.acr.org/docs/3098416/Narrative/">https://acsearch.acr.org/docs/3098416/Narrative/</a></p>
<p><strong>&nbsp;</strong></p>
<p><strong>US shear wave elastography abdomen and &nbsp;MR elastography abdomen is usually appropriate.</strong></p>
<p><strong>MRI abdomen without and with IV contrast, CT abdomen with IV contrast multiphase, MRI abdomen without and with hepatobiliary contrast, MRI abdomen without IV contrast, US abdomen, US duplex Doppler abdomen, US abdomen with IV contrast may be appropriate. </strong></p>
<p><strong>CT abdomen without and with IV contrast, CT abdomen without IV contrast , FDG-PET/CT skull base to&nbsp; mid-thigh is usually not appropriate.</strong></p>
<p><strong>&nbsp;</strong></p>
<p>Imaging plays a vital role in surveillance for HCC in at-risk patients. The patient population with adequate risk to warrant&nbsp; surveillance can&nbsp; loosely&nbsp; be&nbsp; defined&nbsp; as those&nbsp; with&nbsp; chronic&nbsp; viral&nbsp; hepatitis&nbsp; B and&nbsp; cirrhosis of&nbsp; nonvascularcauses, including chronic hepatitis B&nbsp;&nbsp;&nbsp; and C, primary sclerosing cholangitis, and others. Imaging is more effective than serum biomarkers (most notably&alpha;-fetoprotein level)&nbsp; or other techniques for detecting HCC at a treatable stage[42]. Imaging is also critical for characterizing benign, premalignant, and malignant nodules, staging HCC, guiding locoregional ablative treatments, and assessing treatment response.</p>
<p>Cirrhosis due to vascular conditions is a special case in which surveillance for HCC is more complex. Underlyingvascular conditions include Budd-Chiari syndrome, hepatic congestion particularly in the setting of congenital heartdisease,&nbsp; hereditary&nbsp; hemorrhagic&nbsp; telangiectasia,&nbsp; and&nbsp; others.&nbsp; The&nbsp; utility&nbsp; of&nbsp; imaging&nbsp; for diagnosis&nbsp; of&nbsp; cirrhosis andaccuracy for characterizing HCC is less well established, particularly because these patients often develop benign regenerative liver nodules. Optimal utilization of imaging in these patients must be established for each conditionbased on available data and is not addressed in this document.</p>
<p>It should be noted that this document deals specifically with screening and surveillance for HCC, whereas the ACRAppropriateness Criteria&reg;&nbsp; topic&nbsp; on &ldquo;Liver&nbsp; Lesion&mdash;Initial Characterization&rdquo;&nbsp; [43]&nbsp; specifically&nbsp; addresses thecharacterization of liver lesions once they have been detected. The ACR Liver Imaging Reporting and Data Systemalso provides specifics on screening and diagnosis of HCC using CEUS, CT, MRI, and US [44].</p>
<p><strong>CT Abdomen</strong></p>
<p>Data supporting noncontrast CT for HCC screening and surveillance are limited. Multiphase contrast-enhanced CTis highly sensitive for the detection and characterization of HCC, particularly for lesions &gt;2 cm, with sensitivity reported up to 98% [45]. However, multiphase CT with intravenous (IV) contrast suffers from lower sensitivity for smaller&nbsp; lesions,&nbsp; ranging from&nbsp; 40%&nbsp; to&nbsp; 68%&nbsp; [45-48].&nbsp; Additionally,&nbsp; the&nbsp; utility&nbsp; of&nbsp; CT&nbsp; surveillance in&nbsp; a&nbsp; &ldquo;high-risk&rdquo; population, in which expected incidence of HCC development is typically 1.5 to 5% per year, is not well established. CT is not commonly used for HCC surveillance, though it&nbsp;&nbsp; may be useful in patients with obesity or hepatic steatosis in&nbsp; whom&nbsp; the&nbsp; utility of&nbsp; US may&nbsp; be&nbsp; limited. Little&nbsp; value&nbsp; has been&nbsp; demonstrated&nbsp; for the&nbsp; addition&nbsp; of&nbsp; noncontrast&nbsp; to contrast-enhanced CT in this setting</p>
<p><strong>FDG-PET/CT Skull Base to Mid-Thigh</strong></p>
<p>FDG-PET/CT is not a useful test for screening or surveillance for HCC. FDG uptake by HCC is highly variable,and&nbsp; combined with&nbsp; high&nbsp; background liver&nbsp; FDG uptake,&nbsp; the&nbsp; PET&nbsp; portion of&nbsp; these examinations&nbsp; adds&nbsp; little&nbsp; to multiphase contrast-enhanced CT [49]</p>
<p><strong>MR Elastography Abdomen</strong></p>
<p>MR elastography has been investigated for the assessment of focal liver lesions with modest success [50]. However,limited&nbsp; spatial&nbsp; resolution&nbsp; and&nbsp; coverage of&nbsp; MR&nbsp; elastography renders it of&nbsp; limited&nbsp; utility&nbsp; for screening&nbsp; andsurveillance.</p>
<p>&nbsp;</p>
<p><strong>MRI Abdomen</strong></p>
<p>Dynamic contrast-enhanced MRI has been shown to be the most accurate modality in detecting and characterizingHCC, with sensitivity reported between 47% to 95% even for lesions &lt;2 cm [46-48,51-54]. MRI most commonlyserves as a second-line confirmatory diagnostic test for assessing nodules detected with US, though it may have a role&nbsp; for screening&nbsp; and&nbsp; surveillance of&nbsp; patients&nbsp; in&nbsp; whom&nbsp; US&nbsp; is&nbsp; expected&nbsp; to&nbsp; be&nbsp; of&nbsp; lower&nbsp; utility&nbsp; [55].&nbsp; Because thedetection&nbsp; and&nbsp; characterization&nbsp; of&nbsp; HCC&nbsp; relies mainly&nbsp; on the&nbsp; perfusion features of&nbsp; liver&nbsp; lesions,&nbsp; MRI without IVcontrast is not typically performed for this purpose. MRI with hepatobiliary contrast agents has been shown to be similarly sensitive for detection of HCC compared with extracellular agents, and potentially more sensitive (up to 96% in a recent meta-analysis but only 88% in a more recent study) for detection of small lesions [56]. However,challenges with&nbsp; transient&nbsp; respiratory&nbsp; motion&nbsp; artifacts,&nbsp; judging washout,&nbsp; and&nbsp; other&nbsp; technical&nbsp; limitations&nbsp; must&nbsp; be considered [57,58].</p>
<p>Recently, there has been an interest in developing &ldquo;abbreviated&rdquo; MRI techniques for HCC surveillance, in the hopeto&nbsp; take advantage&nbsp; of&nbsp; the&nbsp; modality&rsquo;s&nbsp; high&nbsp; sensitivity&nbsp; for detecting&nbsp; HCC&nbsp; [59-61].&nbsp; Although emerging&nbsp; data are promising, over-detection of nonmalignant nodules remains a substantial challenge, and these techniques remaininvestigational. Future&nbsp; studies&nbsp; showing&nbsp; improvement&nbsp; in&nbsp; survival&nbsp; will&nbsp; be&nbsp; needed&nbsp; to&nbsp; show&nbsp; efficacy&nbsp; of&nbsp; MRI&nbsp; or&ldquo;abbreviated&rdquo;&nbsp; MRI&nbsp; screening. Furthermore,&nbsp; accuracy&nbsp; and&nbsp; potential&nbsp; harms&nbsp; need&nbsp; to&nbsp; be&nbsp; factored&nbsp; into&nbsp; the&nbsp; equation&nbsp; when discussing abbreviated MRI techniques [62].</p>
<p><strong>US Abdomen</strong></p>
<p>Nearly&nbsp; all&nbsp;&nbsp;&nbsp;&nbsp; international guidelines&nbsp; recommend&nbsp; conventional&nbsp; US&nbsp; every&nbsp; 6&nbsp; months&nbsp; as the&nbsp; primary&nbsp; method forsurveillance for HCC &nbsp;[10,13].&nbsp; The&nbsp; only&nbsp; exception&nbsp; is&nbsp; the&nbsp; Japanese Society&nbsp; of&nbsp; Hepatology&nbsp; guideline,&nbsp; whichrecommends the use of US every 3 to 4 months in &ldquo;super-high-risk&rdquo; patients, as well as an optional multiphasic CT or&nbsp; MRI&nbsp; every&nbsp; 6&nbsp; to&nbsp; 12&nbsp; months&nbsp; [55,63].&nbsp; Notably, the&nbsp; Japanese&nbsp; Society&nbsp; of&nbsp; Hepatology&nbsp; recommends&nbsp; the&nbsp; use&nbsp; of&nbsp; USevery 6 months in &ldquo;high-risk patients&rdquo;. Currently, the majority of the prospective evidence proving a survival benefitbased on HCC surveillance is from Asia. A large prospective randomized controlled trial studying the efficacy of US screening was reported from a Chinese cohort of 18,816 patients predominantly with hepatitis B&nbsp;&nbsp;&nbsp; with or without cirrhosis in which a 37% reduction in HCC related mortality was shown. A different large prospective randomized controlled study&nbsp; of&nbsp; 17,920&nbsp; patients&nbsp; in&nbsp; China,&nbsp; showed&nbsp; that&nbsp; patients&nbsp; whose&nbsp; HCC&nbsp; were&nbsp; detected&nbsp; through&nbsp; USsurveillance imaging had a significant improvement in survival of 88% and 78% at 1 and 2 years compared to 0% at 1 and 2 years in those who did not undergo surveillance [64]. In addition, a prospective single mass screening study using US&nbsp; in&nbsp; 8,962 Taiwanese&nbsp; patients showed&nbsp; a&nbsp; 31%&nbsp; reduction&nbsp; in&nbsp; HCC&nbsp; related&nbsp; mortality.&nbsp; Although&nbsp; it&nbsp; is unclear whether the same survival benefit can be realized in the general American population, with a preponderanceof nonhepatitis B related cirrhosis, nonalcoholic steatohepatitis related cirrhosis, and obesity, it is unlikely that such large randomized&nbsp; controlled&nbsp; prospective studies will&nbsp; be&nbsp; performed&nbsp; in&nbsp; the&nbsp; United&nbsp; States&nbsp; due&nbsp; to&nbsp; the&nbsp; ethical&nbsp; ramifications of not performing screening in a lethal yet treatable disease. Nonetheless, several large retrospective cohort&nbsp; studies&nbsp; using&nbsp; US&nbsp; for&nbsp; surveillance&nbsp; in&nbsp; the&nbsp; United&nbsp; States&nbsp; have&nbsp; shown&nbsp; significant&nbsp; survival&nbsp; benefit&nbsp; and&nbsp; early&nbsp; detection of tumors compared to populations without screening and surveillance [65,66].</p>
<p><strong>US Abdomen with IV Contrast</strong></p>
<p>CEUS has been shown to be highly sensitive for the diagnosis of HCC at centers of excellence [14,67,68]. However, CEUS requires focused observation of a single region of interest, and although the ability to reinject after a period of washout allows for more than one region to be evaluated during a single examination, this may not be well-suited for whole-liver assessment as is needed for screening and surveillance [69].</p>
<p><strong>US Shear Wave Elastography Abdomen</strong></p>
<p>The use of SWE has been described for assessment of focal liver lesions in a limited number of small studies [70,71]. However, SWE assessments are typically performed slice by slice; thus, the technique is poorly suited to whole-liver&nbsp; surveillance.&nbsp; To&nbsp; date,&nbsp; most&nbsp; reported&nbsp; investigations&nbsp; on&nbsp; the&nbsp; application&nbsp; of&nbsp; SWE in&nbsp; the&nbsp; liver&nbsp; have&nbsp; focused&nbsp; on liver fibrosis assessment and, to a lesser extent, on differentiating benign from malignant focal lesions.</p>
<p>&nbsp;</p>
<p><strong>US Duplex Doppler Abdomen</strong></p>
<p>Doppler US is typically performed in conjunction with conventional grayscale US assessment. The duplex Doppler component may add value to the grayscale examination, allowing tumor in vein to be more readily identified.</p>

<p><strong>References</strong></p>
<ol>
    <li>Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med2006;144:705-14.</li>
    <li>Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology2010;138:513-21, 21 e1-6.</li>
    <li>Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the&nbsp; development&nbsp; of&nbsp; hepatocellular&nbsp; carcinoma:&nbsp; a&nbsp; meta-analysis&nbsp; of&nbsp; observational&nbsp; studies.&nbsp; Ann&nbsp; Intern&nbsp; Med2013;158:329-37.</li>
    <li>Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol2019;70:151-71.</li>
    <li>Asrani SK,&nbsp; Larson&nbsp; JJ,&nbsp; Yawn&nbsp; B,&nbsp; Therneau&nbsp; TM,&nbsp; Kim&nbsp; WR.&nbsp; Underestimation&nbsp; of&nbsp; liver-related&nbsp; mortality&nbsp; in&nbsp; the&nbsp; United States. Gastroenterology2013;145:375-82 e1-2.</li>
    <li>Tapper EB,&nbsp; Parikh&nbsp; ND.&nbsp; Mortality&nbsp; due&nbsp; to&nbsp; cirrhosis&nbsp; and&nbsp; liver&nbsp; cancer&nbsp; in&nbsp; the&nbsp; United&nbsp; States,&nbsp; 1999-2016: observational study. BMJ2018;362:k2817.</li>
    <li>Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol2002;97:2614-8.</li>
    <li>Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD, American Association for the Study of Liver D. Liver biopsy. Hepatology2009;49:1017-44</li>
</ol>
<p>.9.&nbsp;&nbsp;&nbsp; Parkes J, Guha IN, Roderick P, Rosenberg W. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol2006;44:462-74.</p>
<ol start="10">
    <li>Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology2018;68:723-50.</li>
    <li>Heimbach JK,&nbsp; Kulik&nbsp; LM,&nbsp; Finn&nbsp; RS,&nbsp; et&nbsp; al.&nbsp; AASLD&nbsp; guidelines&nbsp; for&nbsp; the&nbsp; treatment &nbsp;of&nbsp; hepatocellular&nbsp; carcinoma.&nbsp; Hepatology2018;67:358-80.</li>
    <li>Bruix J, Sherman M, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology2011;53:1020-2.</li>
    <li>Omata M,&nbsp; Cheng&nbsp; AL,&nbsp; Kokudo&nbsp; N,&nbsp; et&nbsp; al.&nbsp; Asia-Pacific&nbsp; clinical&nbsp; practice&nbsp; guidelines&nbsp; on&nbsp; the&nbsp; management&nbsp; of&nbsp; hepatocellular carcinoma: a 2017 update. Hepatol Int2017;11:317-70.</li>
    <li>Jang HJ, Kim TK, Wilson SR. Small nodules (1-2 cm) in liver cirrhosis: characterization with contrast-enhanced ultrasound. Eur J Radiol2009;72:418-24.</li>
    <li>Di Lelio A, Cestari C, Lomazzi A, Beretta L. Cirrhosis: diagnosis with sonographic study of the liver surface. Radiology1989;172:389-92.</li>
    <li>Simonovsky V.&nbsp; The&nbsp; diagnosis&nbsp; of&nbsp; cirrhosis&nbsp; by&nbsp; high&nbsp; resolution&nbsp; ultrasound&nbsp; of&nbsp; the&nbsp; liver&nbsp; surface.&nbsp; Br&nbsp; J&nbsp; Radiol1999;72:29-34.</li>
    <li>Torres WE,&nbsp; Whitmire&nbsp; LF,&nbsp; Gedgaudas-McClees&nbsp; K,&nbsp; Bernardino&nbsp; ME.&nbsp; Computed&nbsp; tomography&nbsp; of&nbsp; hepatic&nbsp; morphologic changes in cirrhosis of the liver. J Comput Assist Tomogr1986;10:47-50.</li>
    <li>Ito K, Mitchell DG, Kim MJ, Awaya H, Koike S, Matsunaga N. Right posterior hepatic notch sign: a simple diagnostic MR finding of cirrhosis. J Magn Reson Imaging2003;18:561-6.</li>
    <li>Pickhardt PJ, Malecki K, Kloke J, Lubner MG. Accuracy of Liver Surface Nodularity Quantification on MDCT as a Noninvasive Biomarker for Staging Hepatic Fibrosis. AJR Am J Roentgenol2016;207:1194-99.</li>
    <li>Smith AD,&nbsp; Zand&nbsp; KA,&nbsp; Florez&nbsp; E,&nbsp; et&nbsp; al.&nbsp; Liver&nbsp; Surface&nbsp; Nodularity&nbsp; Score&nbsp; Allows&nbsp; Prediction&nbsp; of&nbsp; Cirrhosis&nbsp; Decompensation and Death. Radiology2017;283:711-22.</li>
    <li>Zissen MH, Wang ZJ, Yee J, Aslam R, Monto A, Yeh BM. Contrast-enhanced CT quantification of the hepatic fractional extracellular&nbsp;&nbsp; space:&nbsp;&nbsp; correlation&nbsp;&nbsp; with&nbsp;&nbsp; diffuse&nbsp;&nbsp; liver&nbsp;&nbsp; disease&nbsp;&nbsp; severity.&nbsp;&nbsp; AJR&nbsp;&nbsp; Am&nbsp;&nbsp; J&nbsp;&nbsp; Roentgenol2013;201:1204-10.</li>
    <li>Varenika V, Fu Y, Maher JJ, et al. Hepatic fibrosis: evaluation with semiquantitative contrast-enhanced CT.Radiology2013;266:151-8.</li>
    <li>Bonekamp D, Bonekamp S, Geiger B, Kamel IR. An elevated arterial enhancement fraction is associated with clinical and imaging indices of liver fibrosis and cirrhosis. J Comput Assist Tomogr2012;36:681-9.</li>
    <li>Bonekamp S,&nbsp; Kamel&nbsp; I,&nbsp; Solga&nbsp; S,&nbsp; Clark&nbsp; J.&nbsp; Can&nbsp; imaging&nbsp; modalities&nbsp; diagnose&nbsp; and&nbsp; stage&nbsp; hepatic&nbsp; fibrosis&nbsp; and&nbsp; cirrhosis accurately? J Hepatol2009;50:17-35.</li>
    <li>Singh S, Venkatesh SK, Wang Z, et al. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. Clin Gastroenterol Hepatol2015;13:440-51 e6.</li>
    <li>Chou CT, Chen RC, Wu WP, Lin PY, Chen YL. Prospective Comparison of the Diagnostic Performance of Magnetic Resonance&nbsp; Elastography&nbsp; with&nbsp; Acoustic&nbsp; Radiation&nbsp; Force&nbsp; Impulse&nbsp; Elastography&nbsp; for&nbsp; Pre-operative Staging of Hepatic Fibrosis in Patients with Hepatocellular Carcinoma. Ultrasound Med Biol2017;43:2783-90.</li>
    <li>Venkatesh SK, Yin M, Ehman RL. Magnetic resonance elastography of liver: technique, analysis, and clinical applications. J Magn Reson Imaging2013;37:544-55.</li>
    <li>Martin DR,&nbsp; Lauenstein&nbsp; T,&nbsp; Kalb&nbsp; B,&nbsp; et&nbsp; al.&nbsp; Liver&nbsp; MRI&nbsp; and&nbsp; histological&nbsp; correlates&nbsp; in&nbsp; chronic&nbsp; liver&nbsp; disease&nbsp; on&nbsp; multiphase gadolinium-enhanced 3D gradient echo imaging. J Magn Reson Imaging2012;36:422-9.</li>
    <li>Wang QB, Zhu H, Liu HL, Zhang B. Performance of magnetic resonance elastography and diffusion-weighted imaging for the staging of hepatic fibrosis: A meta-analysis. Hepatology2012;56:239-47.</li>
    <li>Chen BB,&nbsp; Hsu&nbsp; CY,&nbsp; Yu&nbsp; CW,&nbsp; et&nbsp; al.&nbsp; Dynamic&nbsp; contrast-enhanced&nbsp; magnetic&nbsp; resonance&nbsp; imaging&nbsp; with&nbsp; Gd-EOB-DTPA for the evaluation of liver fibrosis in chronic hepatitis patients. Eur Radiol2012;22:171-80.</li>
    <li>Choi YR, Lee JM, Yoon JH, Han JK, Choi BI. Comparison of magnetic resonance elastography and gadoxetate disodium-enhanced magnetic&nbsp; resonance&nbsp; imaging&nbsp; for&nbsp; the&nbsp; evaluation&nbsp; of&nbsp; hepatic&nbsp; fibrosis.&nbsp; Invest&nbsp; Radiol2013;48:607-13.</li>
    <li>Watanabe H, Kanematsu M, Goshima S, et al. Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging--preliminary observations. Radiology2011;259:142-50.</li>
    <li>Colli A, Colucci A, Paggi S, et al. Accuracy of a predictive model for severe hepatic fibrosis or cirrhosis in chronic hepatitis C. World J Gastroenterol2005;11:7318-22.</li>
    <li>Tchelepi H, Ralls PW, Radin R, Grant E. Sonography of diffuse liver disease. J Ultrasound Med2002;21:1023-32; quiz 33-4.</li>
    <li>Kim G,&nbsp; Shim&nbsp; KY,&nbsp; Baik&nbsp; SK.&nbsp; Diagnostic&nbsp; Accuracy&nbsp; of&nbsp; Hepatic&nbsp; Vein&nbsp; Arrival&nbsp; Time&nbsp; Performed&nbsp; with&nbsp; Contrast-Enhanced Ultrasonography for Cirrhosis: A Systematic Review and Meta-Analysis. Gut Liver2017;11:93-101.</li>
    <li>Nasr P, Hilliges A, Thorelius L, Kechagias S, Ekstedt M. Contrast-enhanced ultrasonography could be a non-invasive method&nbsp; for&nbsp; differentiating&nbsp; none&nbsp; or&nbsp; mild &nbsp;from&nbsp; severe&nbsp; fibrosis&nbsp; in&nbsp; patients&nbsp; with&nbsp; biopsy&nbsp; proven&nbsp; non-alcoholic fatty liver disease. Scand J Gastroenterol2016;51:1126-32.</li>
    <li>Arena U, Vizzutti F, Corti G, et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology2008;47:380-4.</li>
    <li>Millonig G,&nbsp; Reimann&nbsp; FM,&nbsp; Friedrich&nbsp; S,&nbsp; et&nbsp; al.&nbsp; Extrahepatic&nbsp; cholestasis&nbsp; increases&nbsp; liver&nbsp; stiffness&nbsp; (FibroScan)&nbsp; irrespective of fibrosis. Hepatology2008;48:1718-23.</li>
    <li>Hu X, Qiu L, Liu D, Qian L. Acoustic Radiation Force Impulse (ARFI) Elastography for noninvasive evaluation of hepatic fibrosis in chronic hepatitis B and C patients: a systematic review and meta-analysis. Med Ultrason2017;19:23-31.</li>
    <li>Kawanaka H, Kinjo N, Anegawa G, et al. Abnormality of the hepatic vein waveforms in cirrhotic patients with portal hypertension and its prognostic implications. J Gastroenterol Hepatol2008;23:e129-36.</li>
    <li>Oguzkurt L, Yildirim T, Torun D, Tercan F, Kizilkilic O, Niron EA. Hepatic vein Doppler waveform in patients with diffuse fatty infiltration of the liver. Eur J Radiol2005;54:253-7.</li>
    <li>Forner A, Reig M, Bruix J. Alpha-fetoprotein for hepatocellular carcinoma diagnosis: the demise of a brilliant star. Gastroenterology2009;137:26-9.</li>
    <li>American College&nbsp; of&nbsp; Radiology.&nbsp; ACR&nbsp; Appropriateness&nbsp; Criteria&reg;:&nbsp; Liver&nbsp; Lesion&nbsp; &mdash; Initial&nbsp; Characterization.&nbsp; Available at: https://acsearch.acr.org/docs/69472/Narrative/. Accessed November 29, 2019.</li>
    <li>American College&nbsp; of&nbsp; Radiology.&nbsp; Liver&nbsp; Imaging&nbsp; Reporting&nbsp; and&nbsp; Data &nbsp;System&nbsp; (LI-RADS).&nbsp;&nbsp;&nbsp; Available&nbsp; at:&nbsp; http://www.acr.org/quality-safety/resources/LIRADS. Accessed November 29, 2019.</li>
    <li>Luca A, Caruso S, Milazzo M, et al. Multidetector-row computed tomography (MDCT) for the diagnosis of hepatocellular carcinoma in cirrhotic candidates for liver transplantation: prevalence of radiological vascular patterns and histological correlation with liver explants. Eur Radiol2010;20:898-907.</li>
    <li>Akai H, Kiryu S, Matsuda I, et al. Detection of hepatocellular carcinoma by Gd-EOB-DTPA-enhanced liver MRI: comparison with triple phase 64 detector row helical CT. Eur J Radiol2011;80:310-5.</li>
    <li>Inoue T,&nbsp; Kudo&nbsp; M,&nbsp; Komuta&nbsp; M,&nbsp; et&nbsp; al.&nbsp; Assessment&nbsp; of&nbsp; Gd-EOB-DTPA-enhanced&nbsp; MRI&nbsp; for&nbsp; HCC&nbsp; and&nbsp; dysplastic&nbsp; nodules and comparison of detection sensitivity versus MDCT. J Gastroenterol2012;47:1036-47.</li>
    <li>Yu NC, Chaudhari V, Raman SS, et al. CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clin Gastroenterol Hepatol2011;9:161-7</li>
</ol>
<p>.49.&nbsp; Khan&nbsp; MA,&nbsp; Combs&nbsp; CS,&nbsp; Brunt&nbsp; EM,&nbsp; et&nbsp; al.&nbsp; Positron&nbsp; emission&nbsp; tomography&nbsp; scanning&nbsp; in&nbsp; the&nbsp; evaluation&nbsp; of&nbsp; hepatocellular carcinoma. J Hepatol2000;32:792-7.</p>
<ol start="50">
    <li>Ronot M, Vilgrain V. Imaging of benign hepatocellular lesions: current concepts and recent updates. Clin Res Hepatol Gastroenterol2014;38:681-8.</li>
    <li>Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology2008;47:97-104.</li>
    <li>Marrero JA,&nbsp; Hussain&nbsp; HK,&nbsp; Nghiem&nbsp; HV,&nbsp; Umar&nbsp; R,&nbsp; Fontana&nbsp; RJ,&nbsp; Lok&nbsp; AS.&nbsp; Improving&nbsp; the&nbsp; prediction&nbsp; of&nbsp; hepatocellular&nbsp;&nbsp; carcinoma&nbsp;&nbsp; in&nbsp;&nbsp; cirrhotic&nbsp;&nbsp; patients&nbsp;&nbsp; with&nbsp;&nbsp; an &nbsp;&nbsp;arterially-enhancing&nbsp;&nbsp; liver&nbsp;&nbsp; mass.&nbsp;&nbsp; Liver&nbsp;&nbsp; Transpl2005;11:281-9.</li>
    <li>Ooka Y, Kanai F, Okabe S, et al. Gadoxetic acid-enhanced MRI compared with CT during angiography in the diagnosis of hepatocellular carcinoma. Magn Reson Imaging2013;31:748-54.</li>
    <li>Rhee H,&nbsp; Kim&nbsp; MJ,&nbsp; Park&nbsp; MS,&nbsp; Kim&nbsp; KA.&nbsp; Differentiation&nbsp; of&nbsp; early&nbsp; hepatocellular&nbsp; carcinoma&nbsp; from&nbsp; benign&nbsp; hepatocellular nodules on gadoxetic acid-enhanced MRI. Br J Radiol2012;85:e837-44.</li>
    <li>Kudo M. Real practice of hepatocellular carcinoma in Japan: conclusions of the Japan Society of Hepatology 2009 Kobe Congress. Oncology2010;78 Suppl 1:180-8.</li>
    <li>Liu X, Jiang H, Chen J, Zhou Y, Huang Z, Song B. Gadoxetic acid disodium-enhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinoma: A meta-analysis. Liver Transpl2017;23:1505-18.</li>
    <li>Pietryga JA, Burke LM, Marin D, Jaffe TA, Bashir MR. Respiratory motion artifact affecting hepatic arterial phase imaging&nbsp; with&nbsp; gadoxetate&nbsp; disodium:&nbsp; examination&nbsp; recovery&nbsp; with&nbsp; a&nbsp; multiple&nbsp; arterial&nbsp; phase&nbsp; acquisition.&nbsp; Radiology2014;271:426-34.</li>
    <li>Allen BC, Ho LM, Jaffe TA, Miller CM, Mazurowski MA, Bashir MR. Comparison of Visualization Rates of LI-RADS Version 2014 Major Features With IV Gadobenate Dimeglumine or Gadoxetate Disodium in Patients at Risk for Hepatocellular Carcinoma. AJR Am J Roentgenol2018;210:1266-72.</li>
    <li>Marks RM,&nbsp; Ryan&nbsp; A,&nbsp; Heba&nbsp; ER,&nbsp; et&nbsp; al.&nbsp; Diagnostic&nbsp; per-patient&nbsp; accuracy&nbsp; of&nbsp; an&nbsp; abbreviated&nbsp; hepatobiliary&nbsp; phase&nbsp; gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. AJR Am J Roentgenol2015;204:527-35.</li>
    <li>Besa C, Lewis S, Pandharipande PV, et al. Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated&nbsp; MRI&nbsp; protocol&nbsp; combining&nbsp; diffusion-weighted&nbsp; and&nbsp; T1-weighted&nbsp; imaging&nbsp; at&nbsp; the&nbsp; delayed&nbsp; phase post gadoxetic acid. Abdom Radiol (NY)2017;42:179-90.</li>
    <li>Tillman BG, Gorman JD, Hru JM, et al. Diagnostic per-lesion performance of a simulated gadoxetate disodium-enhanced abbreviated MRI protocol for hepatocellular carcinoma screening. Clin Radiol2018;73:485-93.</li>
    <li>2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean J Radiol2019;20:1042-113.</li>
    <li>Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe. Liver Cancer2015;4:85-95.</li>
    <li>Yang B, Zhang B, Xu Y, et al. Prospective study of early detection for primary liver cancer. J Cancer Res Clin Oncol1997;123:357-60.</li>
    <li>Choi DT, Kum HC, Park S, et al. Hepatocellular Carcinoma Screening Is Associated With Increased Survival of Patients With Cirrhosis. Clin Gastroenterol Hepatol2019;17:976-87 e4.</li>
    <li>Singal AG, Mittal S, Yerokun OA, et al. Hepatocellular Carcinoma Screening Associated with Early Tumor Detection and Improved Survival Among Patients with Cirrhosis in the US. Am J Med2017;130:1099-106 e1.</li>
    <li>D'Onofrio M,&nbsp; Faccioli&nbsp; N,&nbsp; Zamboni&nbsp; G,&nbsp; et&nbsp; al.&nbsp; Focal&nbsp; liver&nbsp; lesions&nbsp; in&nbsp; cirrhosis:&nbsp; value&nbsp; of &nbsp;contrast-enhanced ultrasonography compared with Doppler ultrasound and alpha-fetoprotein levels. Radiol Med2008;113:978-91.</li>
    <li>Wang JH, Lu SN, Hung CH, et al. Small hepatic nodules (&lt; or =2 cm) in cirrhosis patients: characterization with contrast-enhanced ultrasonography. Liver Int2006;26:928-34.</li>
    <li>Claudon M, Dietrich CF, Choi BI, et al. Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasound Med Biol2013;39:187-210.</li>
    <li>Gallotti A, D'Onofrio M, Romanini L, Cantisani V, Pozzi Mucelli R. Acoustic Radiation Force Impulse (ARFI) ultrasound imaging of solid focal liver lesions. Eur J Radiol2012;81:451-5.</li>
    <li>Park H, Park JY, Kim DY, et al. Characterization of focal liver masses using acoustic radiation force impulse elastography. World J Gastroenterol2013;19:219-26.</li>
    <li>Doyle DJ, O'Malley ME, Jang HJ, Jhaveri K. Value of the unenhanced phase for detection of hepatocellular carcinomas 3&nbsp; cm&nbsp; or&nbsp; less&nbsp; when&nbsp; performing&nbsp; multiphase&nbsp; computed&nbsp; tomography&nbsp; in&nbsp; patients&nbsp; with&nbsp; cirrhosis.&nbsp; J&nbsp; Comput Assist Tomogr2007;31:86-92.</li>
    <li>Iannaccone R,&nbsp; Laghi&nbsp; A,&nbsp; Catalano&nbsp; C,&nbsp; et&nbsp; al.&nbsp; Hepatocellular&nbsp; carcinoma:&nbsp; role&nbsp; of&nbsp; unenhanced&nbsp; and&nbsp; delayed&nbsp; phase&nbsp; multi-detector row helical CT in patients with cirrhosis. Radiology2005;234:460-7.</li>
    <li>Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology2014;272:635-54.</li>
    <li>European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol2012;56:908-43.</li>
    <li>Wang XY, Chen D, Zhang XS, Chen ZF, Hu AB. Value of (1)(8)F-FDG-PET/CT in the detection of recurrent hepatocellular carcinoma&nbsp; after&nbsp; hepatectomy&nbsp; or&nbsp; radiofrequency&nbsp; ablation:&nbsp; a&nbsp; comparative&nbsp; study&nbsp; with&nbsp; contrast-enhanced ultrasound. J Dig Dis2013;14:433-8.</li>
    <li>NCCN Clinical&nbsp; Practice&nbsp; Guidelines&nbsp; in&nbsp; Oncology.&nbsp; Hepatobiliary&nbsp; Cancers.&nbsp; Version&nbsp; 1.2018.&nbsp;&nbsp;&nbsp; Available&nbsp; at:&nbsp; https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf. Accessed November 29, 2019.</li>
    <li>Roberts LR,&nbsp; Sirlin&nbsp; CB,&nbsp; Zaiem&nbsp; F,&nbsp; et&nbsp; al.&nbsp; Imaging&nbsp; for&nbsp; the&nbsp; diagnosis&nbsp; of&nbsp; hepatocellular&nbsp; carcinoma:&nbsp; A&nbsp; systematic&nbsp; review and meta-analysis. Hepatology2018;67:401-21.</li>
    <li>Jiang T, Zhao Q, Huang M, Sun J, Tian G. Contrast-Enhanced Ultrasound in Residual Tumor of Hepatocellular Carcinoma following&nbsp; Transarterial&nbsp; Chemoembolization:&nbsp; Is&nbsp; It&nbsp; Helpful&nbsp; for&nbsp; Tumor&nbsp; Response?&nbsp; Biomed&nbsp; Res&nbsp; Int2018;2018:8632069.</li>
    <li>Cao J,&nbsp; Dong&nbsp; Y,&nbsp; Mao&nbsp; F,&nbsp; Wang&nbsp; W.&nbsp; Dynamic&nbsp; Three-Dimensional&nbsp; Contrast-Enhanced&nbsp; Ultrasound&nbsp; to&nbsp; Predict&nbsp; Therapeutic Response of Radiofrequency Ablation in Hepatocellular Carcinoma: Preliminary Findings. Biomed Res Int2018;2018:6469703.</li>
    <li>Hu J, Bhayana D, Burak KW, Wilson SR. Resolution of indeterminate MRI with CEUS in patients at high risk for hepatocellular carcinoma. Abdom Radiol (NY)2019:[E-pub ahead of print].</li>
    <li>Zhang P, Zhou P, Tian SM, Qian Y, Deng J, Zhang L. Application of acoustic radiation force impulse imaging for the evaluation of focal liver lesion elasticity. Hepatobiliary Pancreat Dis Int2013;12:165-70.</li>
    <li>American College&nbsp; of&nbsp; Radiology.&nbsp; ACR&nbsp; Appropriateness&nbsp; Criteria&reg;&nbsp; Radiation&nbsp; Dose&nbsp; Assessment&nbsp; Introduction.&nbsp; Available&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;at:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; https://www.acr.org/-/media/ACR/Files/Appropriateness-Criteria/RadiationDoseAssessmentIntro.pdf. Accessed November 29, 2019</li>
</ol>
<p>&nbsp;</p>

</body>
</html>